SEERHealthcare · BiotechnologyThe 2 Wall Street analysts covering Seer, Inc. (California) hold a median 12-month price target of $4 — +106.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 29 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Seer, Inc. (California) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (94): The share count has been shrinking and the company is not leaning on new borrowing.
Value (22): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SEER, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +106.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 May 2026 | Canaccord Genuity | Initiates | Buy | $4.00 |
| 4 May 2026 | Canaccord Genuity | Initiates | Buy | — |
| 13 Aug 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 5 Mar 2024 | Morgan Stanley | Reinstates | Equal-Weight | $7.00 |
| 21 Feb 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 4 Jan 2023 | B of A Securities | Downgrade | Underperform | — |
| 10 Nov 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 Aug 2022 | JP Morgan | Downgrade | Neutral | — |
| 11 Aug 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 5 May 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 1 Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 13 Aug 2021 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2021 | Morgan Stanley | Maintains | Equal-Weight | — |
| 30 Mar 2021 | Morgan Stanley | Maintains | Equal-Weight | — |
| 29 Dec 2020 | Cowen & Co. | Initiates | Outperform | — |
| 29 Dec 2020 | JP Morgan | Initiates | Overweight | — |
| 29 Dec 2020 | Morgan Stanley | Initiates | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SEER appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Seer, Inc. (California) returned −12.6% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 17% of US stocks
Cheaper than 83% of US stocks
Cheaper than 60% of US stocks
Higher than 10% of US stocks
Higher than 19% of US stocks
Higher than 58% of US stocks
Higher than 7% of US stocks
Higher than 96% of US stocks
Higher than 29% of US stocks
Higher than 22% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Seer, Inc. (California) has a market value of $107.4M and an enterprise value of −$23.0M.
Revenue in the twelve months to 30 June 2026: $13.8M. The latest quarter shrank 23.4% year on year.
Net income over the same four quarters: −$68.0M, a −494.3% net margin.
Diluted earnings per share, trailing twelve months: $−1.22.
Free cash flow in the twelve months to 30 June 2026: −$44.2M.
Seer, Inc. (California) spent $5.0M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: −1.5×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Seer, Inc. (California) employs 124 people — $111K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Seer, Inc. (California) — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seer said its Special Committee completed its review and rejected the recent acquisition proposals. The company will remain independent.
Why it matters — SEER watchers may want to note the outcome of the review and the company’s stated independent status.
Seer announced it will report its third-quarter 2026 financial results on November 10, 2026. Management will host a webcast conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Why it matters — SEER watchers can note the date and time when the company plans to discuss its quarterly results.
Seer announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K proteomics study at the 2026 Human Proteome Organization (HUPO) World Congress, held September 27 to October 1 at Suntec Singapore Convention & Exhibition Centre.
Why it matters — A SEER watcher would care because the presentation highlights progress from a major collaborative proteomics study involving Seer's platform at an international scientific conference.
Seer, Inc. announced that President, Chief Financial Officer and Treasurer David Horn will depart the company effective October 1, 2026, to pursue a new opportunity at a private company. The announcement was made on September 21, 2026.
Why it matters — A CFO transition is a significant leadership change that SEER watchers would follow for its potential impact on the company's financial stewardship and executive stability.
Seer announced that it has surpassed 100 peer-reviewed customer publications, six years after its foundational Nature Communications paper. These studies, spanning three continents, demonstrate the value of deep, unbiased proteomics across genetics, aging, disease biology, and population health.
Why it matters — Growing independent, peer-reviewed customer research serves as third-party validation of Seer's technology and its real-world adoption across diverse fields.
The 2 Wall Street analysts covering Seer, Inc. (California) have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Seer, Inc. (California), 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seer, Inc. (California) 80 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, Seer, Inc. (California) ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (94 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +106.2% from the last close, and Ticker Nerd's factor model ranks Seer, Inc. (California) 80 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Seer, Inc. (California) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SEER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
Seer, Inc. (California) returned -12.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Seer, Inc. Class A Common Stock represents ownership in Seer, a life sciences company focused on proteomics.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Seer to Remain an Independent Public Company Following Conclusion of Special Committee Review Process". Seer said its Special Committee completed its review and rejected the recent acquisition proposals. The company will remain independent.
Seer, Inc. Class A Common Stock represents ownership in Seer, a life sciences company focused on proteomics. Seer develops and commercializes the Proteograph Product Suite, an integrated platform that combines proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to support high-throughput protein analysis. Its products are designed for research use in academic institutions, biotechnology and biopharmaceutical companies, and other scientific laboratories seeking deeper, more unbiased insights into biological samples. By enabling protein profiling at scale, Seer plays a specialized role in the broader tools-and-services segment of the life sciences market, where proteomic technologies support biomarker discovery, drug research, and translational science. The company is headquartered in Redwood City, California.
CEO Dr. Omid C. Farokhzad M.D., Ph.D. · 124 employees · United States · https://seer.bio
